Michael Andriole
Chief Executive Officer at CHIMERIX, INC.
Net worth: 473 842 $ as of 2024-03-30
Michael Andriole active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CHIMERIX, INC. | Director/Board Member | 2023-07-31 | - |
| Chief Executive Officer | 2023-07-31 | - | |
| President | 2023-07-31 | - | |
| Director of Finance/CFO | 2019-05-30 | 2023-07-31 | |
| Corporate Officer/Principal | 2019-04-07 | 2019-05-30 |
Career history of Michael Andriole
Former positions of Michael Andriole
| Companies | Position | Start | End |
|---|---|---|---|
| ENDOCYTE, INC. | Director of Finance/CFO | 2017-02-20 | 2018-11-30 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 2006-07-31 | 2017-01-31 |
Training of Michael Andriole
| Kelley School of Business | Masters Business Admin |
| Williams College of Business | Undergraduate Degree |
Statistics
International
| United States | 6 |
Operational
| Director of Finance/CFO | 2 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| CHIMERIX, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
- Stock Market
- Insiders
- Michael Andriole
- Experience
